Eisai
TSE:4523equityPrevious close
4,450
Open
4,455
Day's range
4,452 – 4,529
52-week range
3,660 – 5,349
Volume
730,600
Currency
JPY
About Eisai
Eisai Co., Ltd. is a Japanese pharmaceutical company specializing in the research, development, and marketing of prescription medicines. The company focuses on treatments for neurological disorders, oncology, and other therapeutic areas. Eisai operates primarily in Japan but has a significant global presence, including partnerships in Europe and the United States.
Why investors watch it
Eisai is closely watched by foreign investors due to its strong position in the pharmaceutical sector, particularly in neurodegenerative disease treatments. As one of Japan's leading drugmakers, it offers exposure to the domestic healthcare market while actively expanding its global footprint through strategic partnerships and investments. Recent collaborations with UK institutions highlight its commitment to innovation and international growth.
News
All news →No news found for Eisai.
Press Releases
All releases →Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
17 Jul 2026
JCN Newswireエーザイ、自社創製の不眠症治療薬レンボレキサントの販売承認申請を欧州医薬品庁が受理
16 Jul 2026
JCN NewswireLEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
15 Jul 2026
JCN NewswireFDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
15 Jul 2026
JCN NewswireEisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
15 Jul 2026
JCN NewswireLEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
13 Jul 2026
JCN Newswireエーザイ：「レケンビ」皮下注オートインジェクター、早期アルツハイマー病において静脈内投与製剤と同等の有効性および安全性を支持する臨床データを AAIC 2026 で発表
13 Jul 2026
JCN NewswireEisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
2 Jul 2026
JCN NewswireUCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
2 Jul 2026
JCN Newswireエーザイ、自社創製の不眠症治療薬レンボレキサントの販売承認申請が英国の医薬品・医療製品規制庁により受理
2 Jul 2026
JCN Newswireエーザイ、抗がん剤タレトレクチニブについて進行 ROS1 陽性 非小細胞肺がん治療に係る販売承認申請が英国で受理
26 Jun 2026
JCN NewswireEisai Announces Strategic Investment Supported by the UK Government's LSIMF
17 Jun 2026
Company Milestones
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
Market data is indicative and delayed 15–20 min. Not investment advice.